Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUNCIST: Calmangafodipir in Healthy Japanese and Caucasian Subjects
NCT03430999Phase 1Completed
- Sponsor
- Egetis Therapeutics
- Start
- Nov 2017
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of calmangafodipir in chemotherapy-induced peripheral neuropathy (CIPN) (4 arms), sponsored by Egetis Therapeutics. Primary endpoint: Number of treatment-emergent adverse events at Day 10. Started Nov 2017; status: completed.
02
Drugs
calmangafodipir
03
Conditions
chemotherapy-induced peripheral neuropathy (CIPN)
Beyond the preview
Go deeper on NCT03430999.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03430999.